Zacks
0
All posts from Zacks
Zacks in Our Research. Your Success.,

Regeneron, Intellia Strike Deal for CRISPR/Cas Platform

Regeneron Pharmaceuticals, Inc. REGN announced that it has entered into a six-year licensing and collaboration agreement with Intellia Therapeutics, Inc. to advance the CRISPR/Cas gene-editing technology for in vivo therapeutic development. The companies will also focus on technology development of the CRISPR/Cas platform.

Under the terms of the agreement, Regeneron has exclusive rights to discover and develop CRISPR-based products against as many as 10 targets, focused primarily on a range of diseases that can be potentially treated by editing genes in the liver. Regeneron can select up to 5 non-liver targets out of 10.

In exchange, Intellia will receive an upfront payment of $75 million from Regeneron. Intellia will also be eligible to receive significant milestone and royalty payments on potential Regeneron products. Moreover, the companies have agreed to co-develop and co-commercialize a certain number of targets that are generated during the collaboration.

Meanwhile, Regeneron will be investing up to $50 million in Intellia's next equity financing.

We remind investors that Regeneron has been pursuing strategic collaboration in order to develop the candidates in its pipeline. Earlier this month, the company entered into a licensing agreement with MedImmune, the global biologics research and development arm of AstraZeneca plc AZN, to produce antibody drug conjugates, using MedImmune’s pyrrolobenzodiazepine (PBD)-based warhead and linker technology for the treatment of cancer.

Regeneron currently has a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the health care sector are AMAG Pharmaceuticals, Inc. AMAG and Emergent BioSolutions, Inc. EBS,  both sporting a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
ASTRAZENECA PLC (AZN): Free Stock Analysis Report
 
AMAG PHARMA INC (AMAG): Free Stock Analysis Report
 
REGENERON PHARM (REGN): Free Stock Analysis Report
 
EMERGENT BIOSOL (EBS): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research